Ji Min Health: A subsidiary of the company has obtained an acceptance notice for the clinical trial application for the drug.

The Jimei Health announcement states that the drug DB006 oncolytic adenovirus injection developed by its holding subsidiary, Hainan Jimei Boao International Hospital Co., Ltd., has officially obtained approval for Phase I clinical research application from the National Medical Products Administration. This drug is a gene therapy medication for the treatment of advanced malignant solid tumors. Currently, there are a total of 5 oncolytic virus drugs approved for market globally, with approximately 7 drugs in the domestic market in Phase I/II clinical trial stage. The company will promptly disclose project progress and remind investors to be cautious of risks.